Publications by the researcher in collaboration with Iván Márquez Rodas (20)

2026

  1. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

    Clinical and Translational Oncology, Vol. 28, Núm. 2, pp. 645-653

  2. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

    Clinical and Translational Oncology, Vol. 28, Núm. 5, pp. 1807-1814

  3. Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

    Clinical and Translational Oncology, Vol. 28, Núm. 1, pp. 320-329

  4. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

    Clinical and Translational Oncology, Vol. 28, Núm. 6, pp. 2377-2385

2025

  1. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology, Vol. 27, Núm. 1, pp. 386-391

  2. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

    Melanoma Research, Vol. 35, Núm. 6, pp. 399-408

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2019

  1. A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1754-1762

  2. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2018

  1. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

    Therapeutic Advances in Medical Oncology, Vol. 10

2017

  1. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study

    Medicine, Vol. 96, Núm. 52, pp. e9523

  2. Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  3. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

  4. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  5. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

2016

  1. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study

    PLoS ONE, Vol. 10, Núm. 4

  2. Immune checkpoint inhibitors: Therapeutic advances in melanoma

    Annals of Translational Medicine, Vol. 3, Núm. 18